


FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
 SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-742-E (400/130)	10/664,668
		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		September 18, 2003	1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
/TCG/	*	US 2003/0190635	10/2003	McSwiggen et al.			
/TCG/	*	US 2003/0206887	11/2003	Morrissey et al.			

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/TCG/	*	6,346,398	02/12/02	Pavco et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
/TCG/	1.	1325955	07/09/03	EP (Klippel-Giese et al.)				
/TCG/	2.	08208687	08/1996	JP (Hotoda et al.)	ONLY ABSTRACT CONSIDERED!			
/TCG/	3.	94/11499	05/26/94	WO (Ullrich et al.)				

EXAMINER	/Terra Cotta Gibbs/	DATE CONSIDERED	12/13/2007
----------	---------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		02-742-E (400/130)	10/664,668
		Applicant: McSwiggen et al.	
		Filing Date:	Group:
		September 18, 2003	1635

/TCG/	4.	94/21791	09/29/94	WO (Bergmann et al.)				
	5.	95/04142	02/09/95	WO (Robinson)				
	6.	95/13380	05/18/95	WO (Draper et al.)				
	7.	97/00957	01/09/97	WO (Patterson-Winston et al.)				
	8.	97/21808	06/19/97	WO (Robinson)				
	9.	99/04819	02/04/99	WO (Klimuk et al.)				
	10.	99/55857	11/04/99	Wo (Beigelman et al.)				
	36.	00/21560	04/20/00	WO (Alitalo et al.)				
	11.	01/097850	12/27/01	WO (Siemeister et al.)				
	12.	02/07747	01/31/02	WO (King)				
	13.	02/10378	02/07/02	WO (Cowsert et al.)				
	14.	02/096927	12/05/02	WO (Escobdeo et al.)				
	15.	03/068797	08/21/03	WO (Rossi et al.)				
	16.	03/070887	08/28/03	WO (McSwiggen et al.)				
	17.	03/070896	08/28/03	WO (McSwiggen et al.)				
	18.	03/070910	08/28/03	WO (McSwiggen et al.)				
	19.	03/074654	09/12/03	WO (McSwiggen et al.)				
	20.	03/080638	10/02/03	WO (Lacasse et al.)				
/TCG/	21.	04/009769	01/29/04	WO (Tolentino et al.)				

EXAMINER /Terra Cotta Gibbs/	DATE CONSIDERED 12/13/2007
--	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		02-742-E (400/130)	10/664,668
(Use several sheets if necessary)		Applicant:	
		McSwiggen et al.	
		Filing Date:	Group:
		September 18, 2003	1635

/TCG/	22.	04/043977	05/27/04	WO (Prakush et al.)				
/TCG/	23.	04/072261	08/26/04	WO (Li et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/TCG/	24.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," <i>Oligonucleotides</i> , 13:303-312 (2003)
	25.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
	26.	International Search Report for PCT/US03/05022 mailed January 6, 2005
	27.	International Search Report for PCT/US2004/016390 mailed March 31, 2005
	28.	International Search Report for PCT/US2004/027403 mailed July 12, 2005
	29.	International Search Report for PCT/US2004/030488 mailed January 12, 2005
	30.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)
	31.	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
	32.	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," <i>Cancer Gene Therapy</i> , 10, Suppl. 1, S4-S5 (2003)
	33.	Parry et al. 1999. "Bioactivity of anti-angiogenic ribozymes targeting <i>Flt-1</i> and <i>KDR</i> mRNA," <i>Nucleic Acid Res.</i> 27:2569-77
↓	34.	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 5:519-524 (1990)
/TCG/	35.	Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic & Endocrine</i> , 703-718 (2001)

EXAMINER	/Terra Cotta Gibbs/	DATE CONSIDERED	12/13/2007
----------	---------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

NOV 02 2006

**SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application No.	10/664,668
Filing Date:	September 18, 2003
First Named Inventor	McSwiggen et al.
Art Unit	1635
Examiner Name	unassigned TC Gibbs
Attorney Docket Number	02-742-E (400/130)

Sheet

1

of

2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/TCG/	A	US-5,587,471	12-1996	Cook et al.	
↓	B	US-5,916,763	06-1999	Williams et al.	
↓	C	US-6,710,174	03-23-2004	Bennett et al.	
↓	D	US-2003/0186920	10-2003	Sirois, Martin G.	
↓	E	US-2003/0216335	11-2003	Lockridge et al.	
↓	F	US-2004/0018176	01-2004	Tolentino et al.	
/TCG/	G	US-2004/0209832	10-2004	McSwiggen et al.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/TCG/	1	Caplen, Nathan, "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> 3(4):575-586 (2003)	
↓	2	Hammond, et al., "Post-transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature Reviews</i> , 2:110-119 (2001)	
↓	3	Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," <i>Expert Opin. Drug Deliv.</i> , 2(1):3-28 (2005)	
↓	4	Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," <i>Nature Biotechnology</i> , 21:12, 1457-1465 (2003)	
/TCG/	5	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	12/13/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application No.	10/664,668
				Filing Date:	September 18, 2003
				First Named Inventor	McSwiggen et al.
				Art Unit	1635
				Examiner Name	unassigned TC Gibbs
Sheet	2	of	2	Attorney Docket Number	02-742-E (400/130)

/TCG/	6	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>The Journal of Biological Chemistry</i> , 278:9, 7108-7118 (2003)	
/TCG/	7	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-based Knock-Down Technology," <i>Current Pharmaceutical Biotechnology</i> , 5, 1-7 (2004)	

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	12/13/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 02-742-E (400.130)	Serial No. 10/664,668
	Applicant: McSwiggen et al.	
	Filing Date: September 18, 2003	Group: 1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
/TCG/	*	US 2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US 2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US 2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US 2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US 2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US 2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US 2005/0020521	09/25/03	Rana, Tariq M.			01/27/05
	*	US 2005/0171039	05/11/04	McSwiggen et al.			08/04/05
	*	US 2005/0182005	05/13/04	Tuschl et al.			02/18/05
/TCG/	*	US 2005/0227256	11/26/04	Hutvagner et al.			10/13/05

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/TCG/	*	5,587,471	12/24/96	Cook et al.			
/TCG/	*	5,998,148	12/07/99	Bennett et al.			

EXAMINER /Terra Cotta Gibbs/	DATE CONSIDERED 12/13/2007
--	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 02-742-E (400.130)	Serial No. 10/664,668
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: September 18, 2003	Group: TEB 1635

/TCG/	*	5,998,206	12/07/99	Cowsert			
↓	*	6,060,456	05/09/00	Arnold et al.			
	*	6,214,805	04/10/01	Torrence et al.			
	*	6,346,398	02/12/02	Pavco et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,824,972	11/30/04	Kenwrick et al.			
V	*	7,022,828	04/04/06	McSwiggen et al.			
/TCG/	*	7,078,196	07/18/06	Tuschi et al.			

FOREIGN PATENT DOCUMENTS


		Document Number	Date	Country	Class	Subclas s	Translation	
							Yes	No
/TCG/	1.	1389637	08/05/02	EP (Klippel et al.)				
/TCG/	2.	03/044188	05/30/03	WO (Tei et al.)	ONLY ABSTRACT		CONSIDERED	
/TCG/	3.	04/029212	04/08/04	WO (Rana, Tariq M.)				
/TCG/	4.	04/090105	10/21/04	WO (Leake et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/TCG/	5.	Alexeev et al., "Localized in vivo genotypic and phentypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
-------	----	---

EXAMINER /Terra Cotta Gibbs/	DATE CONSIDERED 12/13/2007
--	--------------------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No.	Serial No.
	02-742-E (400.130)	10/664,668
	Applicant: McSwiggen et al.	
	Filing Date: September 18, 2003	Group:  1635

/TCG/	6.	Bellon et al., "4-Thio-oligo- β -D-ribonucleotides: synthesis of β -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
	7.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (2001)
	8.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
	9.	Braasch et al., "RNA Inteference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
	10.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
	11.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
	12.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
	13.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
	14.	Hornung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
	15.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
	16.	Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
↓	17.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
/TCG/	18.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)

EXAMINER /Terra Cotta Gibbs/	DATE CONSIDERED 12/13/2007
--	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 02-742-E (400.130)	Serial No. 10/664,668
			Applicant: McSwiggen et al.	
			Filing Date: September 18, 2003	Group:  1635

**THIRD SUPPLEMENTAL
 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**

(Use several sheets if necessary)

/TCG/	19.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
	20.	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
	21.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
	22.	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
	23.	Pavco et al., "Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors," <i>Clinical Cancer Research</i> 6:2094-2103 (2000)
	24.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
↓	25.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <i>Nucleic Acids Research</i> 21:5600-5603 (1993)
/TCG/	26.	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>Journal of Biological Chemistry</i> , 278, 7108-7118 (2003)

EXAMINER /Terra Cotta Gibbs/	DATE CONSIDERED 12/13/2007
--	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.